Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up

Eur J Cancer Care (Engl). 2021 Jul;30(4):e13429. doi: 10.1111/ecc.13429. Epub 2021 Feb 22.

Abstract

Objective: Circulating tumour DNA (ctDNA) is emerging as a potential option to detect disease recurrence in many cancer types, however, ensuring patient acceptability of changing clinical practice and the introduction of new technology is paramount.

Methods: Patients enrolled in a non-intervention cohort study determining the ability of ctDNA to detect recurrent endometrial cancer (EC) were invited to participate in a semi-structured interview. Analysis was performed by Template Analysis.

Results: Eighteen patients were interviewed. A ctDNA blood test was viewed by participants as more physically and psychologically acceptable than clinical examination to monitor for EC recurrence. In particular, participants expressed overwhelming preference for a blood test rather than pelvic examination. Although participants acknowledged that an abnormal ctDNA result could cause anxiety, they expressed a preference to be informed of their results, even if a recurrence was too small to detect radiologically. Explanations for these opinions were a desire for certainty whether their cancer would recur or not, and knowledge would help them be more aware of symptoms that should be reported to their clinician.

Conclusions: ctDNA monitoring to identify EC recurrence appears to be acceptable to patients, and for many, it may be preferable to clinical examination.

Keywords: cancer recurrence; circulating tumour DNA; endometrial cancer; monitoring; patient acceptability.

MeSH terms

  • Biomarkers, Tumor / genetics
  • Circulating Tumor DNA*
  • Cohort Studies
  • Endometrial Neoplasms* / diagnosis
  • Endometrial Neoplasms* / genetics
  • Female
  • Follow-Up Studies
  • Humans
  • Mutation
  • Neoplasm Recurrence, Local / diagnosis

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA